Ardelyx (ARDX) Competitors $6.61 -0.07 (-1.05%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.62 +0.00 (+0.08%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. ABVX, AXSM, RNA, NUVL, MRUS, CRSP, TGTX, ACAD, KRYS, and CYTKShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Abivax (ABVX), Axsome Therapeutics (AXSM), Avidity Biosciences (RNA), Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Abivax Axsome Therapeutics Avidity Biosciences Nuvalent Merus CRISPR Therapeutics TG Therapeutics ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Abivax (NASDAQ:ABVX) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Do analysts prefer ABVX or ARDX? Abivax presently has a consensus price target of $99.43, suggesting a potential upside of 18.35%. Ardelyx has a consensus price target of $11.70, suggesting a potential upside of 77.00%. Given Ardelyx's higher possible upside, analysts plainly believe Ardelyx is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Ardelyx 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10 Which has more volatility & risk, ABVX or ARDX? Abivax has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Is ABVX or ARDX more profitable? Abivax has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Abivax's return on equity of 0.00% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets AbivaxN/A N/A N/A Ardelyx -14.60%-36.57%-13.42% Which has preferable valuation and earnings, ABVX or ARDX? Ardelyx has higher revenue and earnings than Abivax. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbivaxN/AN/A-$190.71MN/AN/AArdelyx$333.61M4.77-$39.14M-$0.23-28.74 Does the media prefer ABVX or ARDX? In the previous week, Abivax had 9 more articles in the media than Ardelyx. MarketBeat recorded 19 mentions for Abivax and 10 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.24 beat Abivax's score of 0.71 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of ABVX or ARDX? 47.9% of Abivax shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryArdelyx beats Abivax on 8 of the 14 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61B$2.59B$5.85B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-28.7423.8575.3425.98Price / Sales4.77529.66514.55181.19Price / CashN/A171.1637.5660.44Price / Book9.055.3712.156.29Net Income-$39.14M$32.95M$3.29B$271.07M7 Day Performance1.38%1.28%0.74%3.87%1 Month Performance14.96%6.09%4.82%4.88%1 Year Performance4.75%-2.15%60.58%26.12% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.6295 of 5 stars$6.61-1.0%$11.70+77.0%+6.3%$1.61B$333.61M-28.7490News CoveragePositive NewsABVXAbivax2.5759 of 5 stars$81.03-0.7%$92.33+13.9%+602.4%$6.12BN/A0.0061News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap DownAXSMAxsome Therapeutics4.8913 of 5 stars$121.28-0.4%$178.00+46.8%+29.1%$6.05B$385.69M-23.92380Positive NewsInsider TradeRNAAvidity Biosciences2.1326 of 5 stars$46.58-4.1%$67.00+43.8%+8.3%$5.99B$10.90M-13.08190Trending NewsAnalyst ForecastInsider TradeGap UpNUVLNuvalent2.9909 of 5 stars$76.58+0.7%$120.80+57.7%-1.5%$5.52BN/A-15.6340Insider TradeMRUSMerus2.9057 of 5 stars$65.84-0.4%$88.75+34.8%+41.6%$4.98B$36.13M-11.9737Positive NewsCRSPCRISPR Therapeutics3.426 of 5 stars$51.83-2.3%$71.60+38.1%+22.6%$4.71B$37.31M-9.55460News CoverageTGTXTG Therapeutics4.216 of 5 stars$29.33+1.3%$46.25+57.7%+38.7%$4.65B$329M79.27290Positive NewsInsider TradeACADACADIA Pharmaceuticals4.378 of 5 stars$25.99-0.9%$28.88+11.1%+48.0%$4.38B$957.80M19.54510News CoverageAnalyst ForecastKRYSKrystal Biotech4.9283 of 5 stars$147.70-2.0%$210.38+42.4%-26.6%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.3843 of 5 stars$35.33-5.4%$71.58+102.6%-5.4%$4.23B$18.47M-6.93250Positive NewsInsider Trade Related Companies and Tools Related Companies ABVX Competitors AXSM Competitors RNA Competitors NUVL Competitors MRUS Competitors CRSP Competitors TGTX Competitors ACAD Competitors KRYS Competitors CYTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
